Publications & Posters Publications & Posters - 2022 SITC 2022: Anti-VISTA antibody HMBD-002 reprograms tumor associated macrophages and promotes cytotoxic T cell response Continue Reading
Publications & Posters Publications & Posters - 2022 SITC 2022: Trial in Progress: A phase 1 first-in-human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies Continue Reading
Publications & Posters Publications & Posters - 2022 Journal for ImmunoTherapy of Cancer: Rationally targeted anti-VISTA antibody that blockades the C-C’ loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner. Continue Reading
Publications & Posters Publications & Posters – 2021 SITC 2021: A Phase 1 First-in-Human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies Continue Reading
Announcements Announcements 2021 Hummingbird Bioscience Announces Publication of Abstract on Anti-VISTA Antibody HMBD-002 at the American Society Of Clinical Oncology (ASCO) 2021 Annual Meeting Continue Reading
Publications & Posters Publications & Posters – 2018 Journal for ImmunoTherapy of Cancer: P477 HMBD-002-V4: A novel anti-VISTA antibody that uniquely binds murine and human VISTA and potently inhibits tumor growth by remodeling the immunosuppressive tumor microenvironment Continue Reading
Publications & Posters Publications & Posters – 2018 Cancer Research, Volume 78, Issue 13, Supplement, AACR Journals: Integrative immune profiling of syngeneic tumor models provides predictive immune signatures for treatment response with HMBD-002, a novel anti-VISTA neutralizing antibody Continue Reading
Publications & Posters Publications & Posters – 2017 Cancer Research, Volume 77, Issue 13, AACR Journals: HMBD-002, a novel neutralizing antibody targeting a specific epitope on the co-inhibitory immune checkpoint receptor VISTA, displays potent anti-tumor effects in pre-clinical models Continue Reading
